Suchergebnisse
Suchergebnisse:
MATE1 (multidrug and toxin extrusion 1) Aliases: none Gene name: Solute carrier family 47 member 1 (SLC47A1) Summary. MATE1 is an apically expressed poly-specific proton antiporter which mediates the efflux of diverse substrates, primarily organic cations, in the kidney and the liver. Following its relatively recent discovery, MATE1 has rapidly ...
Multidrug and toxin extrusion protein 1 (MATE1), also known as solute carrier family 47 member 1, is a protein that in humans is encoded by the SLC47A1 gene. SLC47A1 belongs to the MATE (multidrug and toxic compound extrusion) family of transporters that are found in bacteria, archaea and eukaryotes.
A medication used to treat HR+ HER2- advanced or metastatic breast cancer. A fluoroquinolone antibiotic used to treat infections caused by susceptible bacteria of the upper respiratory tract, skin and skin structures, urinary tract, and prostate, as well as for post-exposure treatment of inhaled anthrax and the plague.
MATE1 is highly expressed in the kidney, liver, skeletal muscle and also in adrenal glands, testes and heart. MATE1 exchanges organic cations against protons both in influx as well as in efflux modes. Methods: Here, we examined the interaction of 25 antineoplastic agents with human MATE1.
Die MATE -Arbeitsumgebung ist die Fortführung von GNOME 2. Sie bietet für Linux und andere Unix-artige Betriebssysteme eine intuitive und attraktive Arbeitsumgebung, die sich der traditionell verwendeten Metaphern bedient. MATE wird aktiv weiterentwickelt, um neue Technologien zu unterstützen, während der traditionelle Umgang mit dem ...
27. Apr. 2018 · The OCT/MATE inhibitor trimethoprim abolished TMAO translocation in MDCK-OCT2-MATE1 cells (p < 0.05). The present data suggest that MATE1 contributes to renal elimination of TMAO. For...
9. Jan. 2009 · H+/organic cation antiporters (multidrug and toxin extrusion: MATE1 and MATE2-K) play important roles in the renal tubular secretion of cationic drugs. We have recently identified a regulatory ...
